Nivolumab,Ipilimumab
BMS
['nivo', 'ipilimumab', 'sclc', 'nsclc', 'nivolumab']
treatment with nivolumab, ipilimumab, and chemotherapy produced enduring survival benefits vs chemotherapy alone in the frontline treatment of patients with advanced nsclc, including the pd-l1 negative and squamous populations. #nsclc #asco23 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.